PVX 410

Drug Profile

PVX 410

Alternative Names: PVX-410; XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer AstraZeneca; Emory University; Massachusetts General Hospital; Merck Sharp & Dohme; OncoPep
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I Breast cancer

Most Recent Events

  • 16 Feb 2018 OncoPep suspends patient enrolment in a phase II trial as the protocol is being modified and moved to another institution in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT02700841)
  • 12 Dec 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in USA (SC) (NCT03362060)
  • 05 Dec 2017 Massachusetts General Hospital and Merck Sharp & Dohme plan a phase Ib trial for Breast cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA (NCT03362060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top